NICE requires further information from Gilead before it can recommend Sovaldi for Hepatitis C.

In draft guidelines the National Institute for Health and Care Excellence (NICE) said it is minded not to recommend Sovaldi (sofosbuvir) from Gilead, despite the drug being linked with cure rates of over 90% in 12 weeks. The Institute conceded that available evidence shows Sovaldi is an effective treatment for chronic Hepatitis C in certain patients, evidence is lacking for some subgroups of patients with chronic Hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.The Committee has therefore requested further information from the manufacturer before it can decide whether sofosbuvir is a cost-effective use of NHS resources.